SCM
ELDN icon

Stonepine Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Stonepine Capital Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-35,000
Closed -$108K – 93
2026
Q1 		$108K Sell
35,000
-858,100
-96% -$2.02M 0.04% 79
2025
Q4 		$1.35M Buy
+893,100
New +$2.12M 0.98% 30
2021
Q1 		– Sell
-167,333
Closed -$2.58M – 31
2020
Q4 		$2.58M Buy
+167,333
New +$3.19M 1.97% 16

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Stonepine Capital Management's ELDN Position: Q2 2026 in Review

Stonepine Capital Management sold out of Eledon Pharmaceuticals (ELDN) in Q2 2026, closing a stake of 35,000 shares — an estimated $108K sold.

Stonepine Capital Management first reported a position in ELDN in Q4 2020 and held it in 3 quarters. The position peaked at $2.58M in Q4 2020. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Stonepine Capital Management reported no remaining Eledon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Stonepine Capital Management sold 35,000 Eledon Pharmaceuticals shares in Q2 2026, an estimated $108K.
  • Stonepine Capital Management first reported a position in Eledon Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Stonepine Capital Management's Eledon Pharmaceuticals position peaked at $2.58M in Q4 2020.
  • 161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.